APA (7th ed.) Citation

Páez, D., Tobeña, M., Fernández-Plana, J., Sebio, A., Virgili, A. C., Cirera, L., . . . Salazar, J. (2019). Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. British Journal of Cancer, 120(2), 190. https://doi.org/10.1038/s41416-018-0348-7

Chicago Style (17th ed.) Citation

Páez, David, et al. "Pharmacogenetic Clinical Randomised Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI with High-dose Irinotecan (HD-FOLFIRI) in Metastatic Colorectal Cancer Patients According to Their UGT1A 1 Genotype." British Journal of Cancer 120, no. 2 (2019): 190. https://doi.org/10.1038/s41416-018-0348-7.

MLA (9th ed.) Citation

Páez, David, et al. "Pharmacogenetic Clinical Randomised Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI with High-dose Irinotecan (HD-FOLFIRI) in Metastatic Colorectal Cancer Patients According to Their UGT1A 1 Genotype." British Journal of Cancer, vol. 120, no. 2, 2019, p. 190, https://doi.org/10.1038/s41416-018-0348-7.